STOCK MARKET BSE NSE

Bharat Biotech's Covaxin shows 77.8 per cent efficacy in phase 3 trial data

Bharat Biotech's Covaxin is one of the three vaccines which are currently being used in India.

Published: 22nd June 2021 04:30 PM  |   Last Updated: 22nd June 2021 05:51 PM   |  A+A-

A vial of the Covaxin vaccine is being displayed by a medical worker.

A vial of the Covaxin vaccine is being displayed by a medical worker. (Photo | AFP)

By Online Desk

Covaxin has shown 77.8 per cent efficacy in phase 3 trial data approved by the Central Drugs Standard Control Organisation.

The delay in submitting phase III data of the vaccine had led to questions being raised at various points of time.

The release of the data comes a short while after two studies showed that Covaxin produces fewer antibodies than Covishield. Many experts had warned against reading too much into the findings and asked people to wait for the Phase 3 trials data then.   

​Covaxin is one of the three vaccines currently being used in India. The other two vaccines are Covishield, manufactured by the Serum Institute of India, and Sputnik V, which was brought to India by Dr Reddy's.

India has administered over 28 crore Covid vaccine jabs till date.

Bharat Biotech is expected to produce 2.6 crore doses of the vaccine in June.

The company developed the vaccine in association with the Indian Council of Medical Research (ICMR).

ALSO WATCH:

(This is a developing story. More details awaited.)



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp